

## SNAPSHOT GARS™

### Coupling Genetic Addiction Risk Score (GARS™) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

**Blum K**, Madigan MA, Fried L, Braverman ER, Giordano J, Badgaiyan RD.

Glob J Addict Rehabil Med. 2017 Feb;1(2). pii: 555556. doi: 10.19080/GJARM.2017.01.555556. Epub 2017 Feb 23. No abstract available.

PMID:29399668 [Free PMC Article](#)

### Genetic addiction risk score (GARS™), a predictor of vulnerability to opioid dependence.

**Blum K**, Chen ALC, Thanos PK, Febo M, Demetrovics Z, Dushaj K, Kovoor A, Baron D, Smith DE, Roy AK III, Fried L, Chen TJH, Chapman E Sr, Modestino EJ, Steinberg B, Badgaiyan RD.

Front Biosci (Elite Ed). 2018 Jan 1;10:175-196. Review.PMID:28930612

### THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS.

**Blum K**, Downs BW, Dushaj K, Li M, Braverman ER, Fried L, Waite R, Demetrovics Z, Badgaiyan RD. Precis Med (Bangalore).

2016;1(1):18-33. Epub 2016 Aug 1.PMID:28066828 [Free PMC Article](#)

### Genetic Addiction Risk Score (GARS™): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

**Blum K**, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS.

Mol Neurobiol. 2014 Dec;50(3):765-96. doi: 10.1007/s12035-014-8726-5. Epub 2014 May 31.PMID:24878765 [Free PMC Article](#)

### Coupling Genetic Addiction Risk Score (GARS™) with Electrotherapy: Fighting Iatrogenic Opioid Dependence.

**Blum K**, Oscar-Berman M, Dinubile N, Giordano J, Braverman ER, Truesdell CE, Barh D, Badgaiyan R.J Addict Res Ther.

2013 Oct 31;4(163):1000163. PMID:24616834 [Free PMC Article](#)

### Dopamine Genetics and Function in Food and Substance Abuse.

**Blum K**, Oscar-Berman M, Barh D, Giordano J, Gold M.

J Genet Syndr Gene Ther. 2013 Feb 10;4(121). pii: 1000121.PMID: 23543775 [Free PMC Article](#)

### The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis.

**Blum K**, Thanos PK, Wang GJ, Febo M, Demetrovics Z, Modestino EJ, Braverman ER, Baron D, Badgaiyan RD, Gold MS.

Curr Pharm Des. 2018 Feb 12;23(39):6050-6061. doi: 10.2174/1381612823666170823101713. PMID: 28831923

### Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility.

**Blum K**, Hauser M, Fratantonio J, Badgaiyan RD.

Addict Genet. 2015 Jul 1;2(1):1-5. Epub 2015 Aug 28. PMID:26807291 [Free PMC Article](#)

### **Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.**

**Blum K**, Badgaiyan RD, Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS.

J Reward Defic Syndr. 2015;1(1):65-68. PMID: 26052557 [Free PMC Article](#)

### **Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?**

**Blum K**, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS.

J Addict Res Ther. 2014;5. pii: 1000185. PMID: 25664200 [Free PMC Article](#)

### **Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation.**

**Blum K**, Febo M, Smith DE, Roy AK 3rd, Demetrovics Z, Cronjé FJ, Femino J, Agan G, Fratantonio JL, Pandey SC, Badgaiyan RD, Gold MS.

J Child Adolesc Psychopharmacol. 2015 May;25(4):286-92. doi: 10.1089/cap.2014.0146. Epub 2015 Apr 28. Review. PMID: 25919973 [Free PMC Article](#)

### **Coupling Neurogenetics (GARSTM) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.**

**Blum K**, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M, Gold MS.

J Reward Defic Syndr. 2015;1(2):75-80. Epub 2015 Jun 24. PMID: 27617300 [Free PMC Article](#)

### **Genospirituality: Our Beliefs, Our Genomes, and Addictions.**

**Blum K**, Thompson B, Oscar-Berman M, Giordano J, Braverman E, Femino J, Barh D, Downs W, Smpatico T, Schoenthaler S.

J Addict Res Ther. 2013 Oct 10;5(4). pii: 162. PMID: 24971227 [Free PMC Article](#)

### **The Benefits of Genetic Addiction Risk Score (GARSTM) Testing in Substance Use Disorder (SUD).**

**Blum K**, Modestino EJ, Gondre-Lewis M, Chapman EJ, Neary J, et al.

(2017)Int J Genom Data Min: IJGD-115. DOI: 10.29014/IJGD-115.000015

### **Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?**

Gold MS, Blum K, Oscar-Berman M, Braverman ER.

Postgrad Med. 2014 Jan;126(1):153-77. doi: 10.3810/pgm.2014.01.2735. Review. PMID: 24393762 [Free PMC Article](#)

### **Epigenetic Modulation of Mood Disorders.**

Archer T, Oscar-Berman M, **Blum K**, Gold M.

J Genet Syndr Gene Ther. 2013 Feb 11;4(120). pii: 1000120. PMID:23565345 [Free PMC Article](#)

### **Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms.**

Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Barh D, Hauser M, Borsten J, Simpatico T.

J Genet Syndr Gene Ther. 2012 Apr 13;3(112). pii: 1000112. PMID: 23336089 [Free PMC Article](#)

### **Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry.**

Archer T, Oscar-Berman M, **Blum K**, Gold M.

J Genet Syndr Gene Ther. 2012 May 30;3(3):1000115. PMID: 23264884 [Free PMC Article](#)

### **Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms.**

**Blum K**, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M.

J Psychoactive Drugs. 2012 Jan-Mar;44(1):38-55. Review. PMID: 22641964 [Free PMC Article](#)

### **Epigenetics in Developmental Disorder: ADHD and Endophenotypes.**

Archer T, Oscar-Berman M, **Blum K**.

J Genet Syndr Gene Ther. 2011 Jun 30;2(104). pii: 1000104. PMID:22224195 [Free PMC Article](#)

### **Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report.**

Chen AL, **Blum K**, Chen TJ, Giordano J, Downs BW, Han D, Barh D, Braverman ER.

Food Funct. 2012 Jan;3(1):40-8. doi: 10.1039/c1fo10089k. Epub 2011 Nov 3. PMID: 22051885

## Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability.

Bowirrat A, Chen TJ, **Blum K**, Madigan M, Bailey JA, Chuan Chen AL, Downs BW, Braverman ER, Radi S, Waite RL, Kerner M, Giordano J, Morse S, Oscar-Berman M, Gold M.

Curr Neuropharmacol. 2010 Dec;8(4):335-58. doi: 10.2174/157015910793358123. PMID: 21629442 [Free PMC Article](#)

## Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.

Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ, Floyd JB, O'Brien D, Liu HH, **Blum K**.

Med Hypotheses. 2009 Jan;72(1):14-22. doi: 10.1016/j.mehy.2008.07.059. Epub 2008 Oct 31. Review. PMID: 18951726 [Free PMC Article](#)

## Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths.

Comings DE, Chen TJ, **Blum K**, Mengucci JF, Blum SH, Meshkin B.

Theor Biol Med Model. 2005 Dec 23;2:50. Review. PMID: 16375770 [Free PMC Article](#)

## Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatric genetic research of complex behavioral disorders.

Chen TJ, **Blum K**, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE.

Med Hypotheses. 2005;65(4):703-7. PMID: 15964153

## Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB).

**Blum K**, Braverman ER, Wu S, Cull JG, Chen TJ, Gill J, Wood R, Eisenberg A, Sherman M, Davis KR, Matthews D, Fischer L, Schnautz N, Walsh W, Pontius AA, Zedar M, Kaats G, Comings DE.

Mol Psychiatry. 1997 May;2(3):239-46. PMID: 9152988

## Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report.

**Blum K**, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG.

Pharmacogenetics. 1996 Aug;6(4):297-305. PMID: 8873216

## The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem.

**Blum K**, Wood RC, Braverman ER, Chen TJ, Sheridan PJ.

Funct Neurol. 1995 Jan-Feb;10(1):37-44. Review. PMID: 7649500

## Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele.

**Blum K**, Braverman ER, Dinardo MJ, Wood RC, Sheridan PJ.

Pharmacogenetics. 1994 Dec;4(6):313-22. PMID: 7704037

## Allelic association of the D2 dopamine receptor gene with cocaine dependence.

Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, Fitch RJ, Ozkaragoz T, Sheridan PJ, Anglin MD, et al.

Drug Alcohol Depend. 1993 Oct;33(3):271-85. Erratum in: Drug Alcohol Depend 1993 Dec;34(1):83-4. PMID: 8261891

## Substance abuse vulnerability and D2 receptor genes.

Uhl G, **Blum K**, Noble E, Smith S.

Trends Neurosci. 1993 Mar;16(3):83-8. Review. PMID: 7681236

## Genetic predisposition in alcoholism: association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics.

**Blum K**, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Ozkaragoz T, Fitch RJ, Wood R, Finley O, Sadlack F. Alcohol.

1993 Jan-Feb;10(1):59-67. PMID: 8095394

## Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism.

**Blum K**, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, Ozkaragoz T, Fitch RJ, Sadlack F, Sheffield D, et al.

Alcohol. 1991 Sep-Oct;8(5):409-16. PMID: 1839129

### **Allelic association of human dopamine D2 receptor gene in alcoholism.**

**Blum K**, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB. *JAMA*. 1990 Apr 18;263(15):2055-60. PMID: 1969501

### **Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.**

Noble EP, **Blum K**, Ritchie T, Montgomery A, Sheridan PJ. *Arch Gen Psychiatry*. 1991 Jul;48(7):648-54. PMID: 2069496

### **Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?**

**Blum K**, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demetrovics Z, Gold MS. *Expert Opin Biol Ther*. 2015 Jul;15(7):973-85. doi: 10.1517/14712598.2015.1045871. Epub 2015 May 14. Review. PMID: 25974314

### **Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.**

**Blum K**, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs WB, Waite RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D, Liu Y, Helman M, Simpatico T. *J Addict Res Ther*. 2012 Nov 27;3(5):139. PMID: 23926462 [Free PMC Article](#)

### **Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour.**

**Blum K**, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. *Pharmacogenetics*. 1995 Jun;5(3):121-41. Review. PMID: 7550364

### **Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause.**

**Blum K**, Gold MS, Jacobs W, McCall WV, Febo M, Baron D, Dushaj K, Demetrovics Z, Badgaiyan RD. *Front Biosci (Landmark Ed)*. 2017 Mar 1;22:1247-1288. Review. PMID: 28199203

### **Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.**

**Blum K**, Febo M, Badgaiyan RD, Demetrovics Z, Simpatico T, Fahlke C, M OB, Li M, Dushaj K, Gold MS. *Curr Neuropharmacol*. 2017;15(1):184-194. Review. PMID: 27174576 [Free PMC Article](#)

### **The genetics of problem and pathological gambling: a systematic review.**

Gyollai A, Griffiths MD, Barta C, Vereczkei A, Urbán R, Kun B, Kökönyei G, Székely A, Sasvári-Székely M, **Blum K**, Demetrovics Z. *Curr Pharm Des*. 2014;20(25):3993-9. Review. PMID: 24001288

### **Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.**

**Blum K**, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. *Med Hypotheses*. 2007;69(5):1054-60. Epub 2007 Apr 30. PMID: 17467918

### **Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: a reappraisal.**

**Blum K**, Sheridan PJ, Wood R, Braverman ER. *Eur Arch Psychiatry Clin Neurosci*. 1995;245(1):50-2. No abstract available. PMID: 7786911

### **Genetic Addiction Risk Score (GARS™) Analysis: Exploratory development of polymorphic risk alleles in poly-drug addicted males.**

**Blum K**, Giordano J, Morse S, Liu Y, Tan J, Bowirrat A, Smolen A, Waite R, Downs W, Madigan M, Kerner M, Fornari F, Stice E, Braverman, E, Miller D, Bailey J. *International J. Omics and Biotechnology*, DOI:<http://www.doaj.org/doaj>, 2010.

### **Addiction Risk Score (GARS™) Analysis: Exploratory Development of Polymorphic risk Alleles in Polydrug addicted males.**

**Blum K**, Giordano j, Morse S, Liu Y, Tain J, Bowirrat A, Smolen A, Waite R, Down B, Madigan M, Kerner M, Fornari F, Barverman E, Miller D, Bailey J. *IIOAB Vol1(20)*, 1-14.

**Differential effects of 5-HTTLPR and DRD2/ANKK1 polymorphisms on electrocortical measures of error and feedback processing in children.**

Althaus M, Groen Y, Wijers AA, Mulder LJ, Minderaa RB, Kema IP, Dijk JD, Hartman CA, Hoekstra PJ.  
Clin Neurophysiol. 2009 Jan;120(1):93-107. doi: 10.1016/j.clinph.2008.10.012. Epub 2008 Nov 28. PMID:19046929

**Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder.**

Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C, Patte K, Hwang R, Kennedy JL.  
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):620-8. doi: 10.1016/j.pnpbp.2007.09.024. Epub 2007 Oct 10. PMID:18262320

**Neurogenetic impairments of brain reward circuitry links to Reward Deficiency Syndrome(RDS) as evidenced by genetic addiction risk score(GARS™): A case study.**

**Blum K**, Han D, Hauser M, Downs BW, Giordano J, Borten J, Winchell W, Simpatico T, Barh D. IIOAB 4(1): 4-9.

**Genetic Addiction Risk Score (GARS™): Testing for Polygenic Predisposition and Risk for Reward Deficiency Syndrome (RDS.)**

**Blum K**, Fornari F, Downs BW, Waite RL, Giordano J, Smolen A, Lui Y, Tain J, Majmundr N, Braverman ER. Chapter 19: in Gene Therapy Applications (Ed. C King) pages 327-362.

**Iatrogenic Opioid Dependence is Endemic and Legal: Coupling Genetic Addiction Risk Score (GARS™) with Electrotherapy as a new paradigm shift in pain relief program.**

**Blum K**, Han D, Oscar-Berman M, Reinl G, DiNubile N, Madigan MA, Bajaj A, Dows BW, Giordano J, Westcott W, Smith L, Braverman Er, Dushaj, Loehmann R, Hauser M, Simpatico T, McLaughlin T, Baley T, Borsten J, Barh D. s. Heath Vol.5, No.11A, 16-34 (2013) Health <http://dx.doi.org/10.4236/health>.

**Hypothesizing benefits of the incorporation of genetic addiction risk (GARSRX™) and Dopamine Agonist Modalities (DAM) in clinical Addiction Medicine.**

**Blum K**, Smith DE, Femini J, Roy AK, Simpatico T, Inaba D, Agan G, Frantantonio J, Febo M, Barh D. (2014) Hypothesizing benefits of the incorporation of genetic addiction risk (GARSRX™) and Dopamine Agonist Modalities (DAM) in clinical Addiction Medicine. Journal of Addiction Therapy & Research. 1(2): 009.

**Quantification of Addiction Risk Utilizing the Genetic Addiction Risk Score (GARS™) in Multiple- Treatment Centers in the United States: Prediction of Addiction Severity Index-Alcohol- Risk Score, Family History and Illicit Drug Abuse.**

**Blum K**, Haberstick BC, Smolen A, Han D, Oscar-Berman M, Smith DE, Simpatico T, Borsten J, Winchel E, Giordano J, Jones S., Braveman Er, Dushaj K, Li M, Hauser M, Campenella C, Femino J, Villapiano A, Butler S, Roy AK, Cook H, McCormick L, Lindsey C, McLaughlin T, Jaffe A, Holiday B, Barh D, Agan G, Frantantonio JL, Marzilli L, Cronjé, F, Demetrovics Z, Baron D, Gold MS (2015). To be submitted to Journal of Addiction Medicine

**Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARS™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine.**

**Blum K**, Smith DE, Femino J, Roy AK, Simpatico T, Inaba D, Agan G, Fratantonio, Febo M, Fornari F, Hauser M, Barh D. JAdd Thpy. 2014, Volume 1, Issue 2: 009

**The A1 allele of the DRD2 gene (Taql A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients.**

Ponce G, Jimenez-Arriero MA, Rubio G, Hoenicka J, Ampuero I, Ramos JA, Palomo T.  
Eur Psychiatry. 2003 Nov;18(7):356-60. PMID:14643564

**Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?**

Green AI, Zimmet SV, Strous RD, Schildkraut JJ.  
Harv Rev Psychiatry. 1999 Mar-Apr;6(6):287-96. Review. PMID:10370435

# SNAPSHOT PRO-DOPAMINE REGULATION

## Synaptamine (SG8839) An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research.

**Blum K**, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshafski M, Braverman ER.

2(2): 132-138, 2007.

## Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS).

**Blum K**, Febo M, Fried L, Baron D, Braverman ER, Dushaj K, Li M, Demetrovics Z, Badgaiyan RD.

J Reward Defic Syndr Addict Sci. 2017;3(1):3-13. Epub 2017 Apr 28. PMID:28804788 [Free PMC Article](#)

## Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns.

Vitali M, Napolitano C, Berman MO, Minuto SF, Battagliese G, Attilia ML, Braverman ER, Romeo M, Blum K, Ceccanti M.

J Addict Res Ther. 2016 Apr;5(2). pii: 182. doi: 10.4172/2155-6105.1000181. Epub 2016 Apr 26. PMID:28090374 [Free PMC Article](#)

## Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

**Blum K**, Febo M, Fried L, Li M, Dushaj K, Braverman ER, McLaughlin T, Steinberg B, Badgaiyan RD.

Subst Use Misuse. 2017 Mar 21;52(4):535-547. doi: 10.1080/10826084.2016.1244551. Epub 2016 Dec 29. PMID: 28033474 [Free PMC Article](#)

## Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.

Duquette LL, Mattiace F, **Blum K**, Waite RL, Boland T, McLaughlin T, Dushaj K, Febo M, Badgaiyan RD.

Clin Med Rev Case Rep. 2016;3(5). pii: 104. doi: 10.23937/2378-3656/1410104. Epub 2016 May 11. PMID:29214221 [Free PMC Article](#)

## Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

**Blum K**, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J.

J Genet Syndr Gene Ther. 2012 Oct 17;3(4). pii: 1000e115. PMID: 23264886 [Free PMC Article](#)

## Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?

McLaughlin T, Han D, Nicholson J, Steinberg B, **Blum K**, Febo M, Braverman E, Li M, Fried L, Badgaiyan R.

J Syst Integr Neurosci. 2017 May;3(3). doi: 10.15761/JSIN.1000165. Epub 2017 Jun 17. PMID: 29423319 [Free PMC Article](#)

## Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

**Blum K**, Oscar-Berman M, Femino J, Waite RL, Benya L, Giordano J, Borsten J, Downs WB, Braverman ER, Loehmann R, Dushaj K, Han D, Simpatico T, Hauser M, Barh D, McLaughlin T.

J Addict Res Ther. 2013 Apr 23;4(2). doi: 10.4172/2155-6105.1000146. PMID: 24273683 [Free PMC Article](#)

## Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.

Miller M, Chen AL, Stokes SD, Silverman S, Bowirrat A, Manka M, Manka D, Miller DK, Perrine K, Chen TJ, Bailey JA, Downs W, Waite RL, Madigan MA, Braverman ER, Damle U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D,

**Blum K**.

J Psychoactive Drugs. 2012 Nov-Dec;44(5):398-409. PMID: 23457891 [Free PMC Article](#)

## Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D<sub>2</sub> agonist therapy: part 2.

**Blum K**, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER.

Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. PMID: 21084796

**Acute intravenous synaptamine complex variant KB220™ “normalizes” neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.**

Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, Smolen A, Stevens E, Yeldandi S, **Blum K**.

Postgrad Med. 2010 Nov;122(6):188-213. doi: 10.3810/pgm.2010.11.2236. Review.PMID: 21084795

**Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.**

Rothman RB, Blough BE, Baumann MH.

AAPS J. 2007 Jan 5;9(1):E1-10. Review.PMID:17408232 [Free PMC Article](#)

**Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders.**

Brown RJ, **Blum K**, Trachtenberg MC.

J Psychoactive Drugs. 1990 Apr-Jun;22(2):173-87. PMID: 2374070

**Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE.**

**Blum K**, Trachtenberg MC, Elliott CE, Dingler ML, Sexton RL, Samuels AI, Cataldie L.

Alcohol. 1988 Nov-Dec;5(6):481-93.PMID: 3072969

**Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study.**

**Blum K**, Trachtenberg MC, Ramsay JC.

Int J Addict. 1988 Sep;23(9):991-8. PMID: 2906910

**Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct.**

**Blum K**, Trachtenberg MC.

J Psychoactive Drugs. 1988 Jul-Sep;20(3):297-313. Review. No abstract available. PMID: 3069987

**Enhancement of attention processing by Kantroll in healthy humans: a pilot study.**

DeFrance JF, Hymel C, Trachtenberg MC, Ginsberg LD, Schweitzer FC, Estes S, Chen TJ, Braverman ER, Cull JG, **Blum K**.

Clin Electroencephalogr. 1997 Apr;28(2):68-75.PMID: 9137870

**Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine.**

Trachtenberg MC, **Blum K**.

J Psychoactive Drugs. 1988 Jul-Sep;20(3):315-31. Review. No abstract available. PMID: 2907000

**Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.**

**Blum K**, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Demetrovics Z.

Curr Pharm Des. 2016;22(38):5837-5854. Review.PMID: 27510492

**Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.**

**Blum K**, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Thanos PK, Demetrovics Z, Febo M.

J Reward Defic Syndr Addict Sci. 2016;2(1):14-21. doi: 10.17756/jrdsas.2016-023. Epub 2016 Jun 29.PMID: 28317038 [Free PMC Article](#)

**Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis.**

McLaughlin T, **Blum K**, Oscar-Berman M, Febo M, Demetrovics Z, Agan G, Fratantonio J, Gold MS.

J Reward Defic Syndr. 2015;1(1):24-35. PMID: 26065033 [Free PMC Article](#)

**rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.**

**Blum K**, Liu Y, Wang W, Wang Y, Zhang Y, Oscar-Berman M, Smolen A, Febo M, Han D, Simpatico T, Cronjé FJ, Demetrovics Z, Gold MS.

Postgrad Med. 2015 Mar;127(2):232-41. Epub 2014 Dec 16. PMID: 25526228 [Free PMC Article](#)

**Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.**

Chen TJ, **Blum K**, Payte JT, Schoolfield J, Hopper D, Stanford M, Braverman ER.  
Med Hypotheses. 2004;63(3):538-48. PMID: 15288384

**Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.**

**Blum K**, Febo M, Badgaiyan RD.  
Austin Addict Sci. 2016;1(2). pii: 1006. Epub 2016 Oct 12. PMID: 27840857 [Free PMC Article](#)

**Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD.**

McLaughlin T, **Blum K**, Steinberg B, Modestino EJ, Fried L, Baron D, Siwicki D, Braverman ER, Badgaiyan RD.  
J Behav Addict. 2018 Mar 1;7(1):192-203. doi: 10.1556/2006.6.2017.081. Epub 2018 Jan 10. PMID: 29316800

**Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case.**

Steinberg B, **Blum K**, McLaughlin T, Lubar J, Febo M, Braverman ER, Badgaiyan RD.  
Open J Clin Med Case Rep. 2016;2(11). pii: 1121. PMID: 27610420 [Free PMC Article](#)

**KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?**

McLaughlin T, Febo M, Badgaiyan RD, Barh D, Dushaj K, Braverman ER, Li M, Madigan MA, **Blum K**.  
J Reward Defic Syndr Addict Sci. 2016;2(1):3-13. doi: 10.17756/jrdsas.2016-022. Epub 2016 May 19. PMID:28210713 [Free PMC Article](#)

**Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.**

Duquette LL, Mattiace F, **Blum K**, Waite RL, Boland T, McLaughlin T, Dushaj K, Febo M, Badgaiyan RD.  
Clin Med Rev Case Rep. 2016;3(5). pii: 104. doi: 10.23937/2378-3656/1410104. Epub 2016 May 11. PMID: 29214221 [Free PMC Article](#)

**Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy.**

McLaughlin T, **Blum K**, Oscar-Berman M, Febo M, Agan G, Fratantonio JL, Simpatico T, Gold MS.  
J Behav Addict. 2015 Jun;4(2):106-15. doi: 10.1556/2006.4.2015.008. PMID: 26132915 [Free PMC Article](#)

**Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT).**

McLaughlin T, Oscar-Berman M, Simpatico T, Giordano J, Jones S, Barh D, Downs WB, Waite RL, Madigan M, Dushaj K, Lohmann R, Braverman ER, Han D, **Blum K**.  
J Behav Addict. 2013 Jun;2(2):117-24. doi: 10.1556/JBA.2.2013.2.8. PMID: 26165932

**"Pro-dopamine regulation (KB220Z™)" as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America.**

**Blum K**, Marcelo F, Dushaj K, Fried L, Badgaiyan RD.  
J Syst Integr Neurosci. 2016 Sep;2(3):162-165. doi: 10.15761/JSIN.1000129. PMID: 28491463 [Free PMC Article](#)

**Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.**

**Blum K**, Whitney D, Fried L, Febo M, Waite RL, Braverman ER, Dushaj K, Li M, Giordano J, Demetrovics Z, Badgaiyan RD.  
Clin Med Rev Case Rep. 2016;3(8). pii: 125. doi: 10.23937/2378-3656/1410125. Epub 2016 Aug 16. PMID:29034323 [Free PMC Article](#)

**Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?**

**Blum K**, Febo M, Thanos PK, Baron D, Fratantonio J, Gold M.  
Mol Neurobiol. 2015 Dec;52(3):1862-1869. doi: 10.1007/s12035-015-9110-9. Epub 2015 Mar 10. Review. PMID: 25750061 [Free PMC Article](#)



**Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study.**

Kushner S, Han D, Oscar-Berman M, William Downs B, Madigan MA, Giordano J, Beley T, Jones S, Barh D, Simpatico T, Dushaj K, Lohmann R, Braverman ER, Schoenthaler S, Ellison D, **Blum K.**

J Addict Res Ther. 2013 Jul 2;4(3). pii: 153.PMID: 24273684 [Free PMC Article](#)

**Pharmacotherapies for Overeating and Obesity.**

Yarnell S, Oscar-Berman M, Avena N, **Blum K,** Gold M.

J Genet Syndr Gene Ther. 2013 Apr 1;4(3):131.PMID: 23826512 [Free PMC Article](#)

**Clinical evidence For Effectiveness of Phencal™ in maintaining weight loss in an open-label, controlled, 2-year study .**

**Blum, K.** Cull, JG. Chen TJH, Garcia-Swan Susan, Holder, JM, Wood, R. Braverman, ER, Buci, LR., & Trachtenberg, MC.

Current Therapeutic Research. 58 (10) 1997.

**Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse**

**Kenneth Blum,** John Giordano, Siobhan Morse, Arthur Anderson, Javier Carbajal, Roger Waite, Bernard Downs, Jaclyn Downs, Margaret Madigan, Debmalya Barh, Eric Braverman

IIOAB Letters Vol 1, No 1, 2011.

**Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30 day inpatient treatment program by the neuronutrient Tropamine'**

**Blum, K.,** Allison, D., Trachtenberg, M.C., Williams, R.W. and Loeblich, L.A.

Curr. Ther. Res. 43:1204 1214, 1988.

**Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects.**

**Kenneth Blum,** Amanda LCin Chen, Thomas JH Chen, Abdalla Bowirrat, Roger L Waite, Mallory Kerner, Seth H. Blum, B. William Downs, Stella Savarimuthu, Patrick Rhoades, Jeffrey Reinking, Eric R. Braverman, Dasha Braverman, Nicholas DiNubile, Marlene Oscar-Berman

Gene Ther Mol Biol Vol 13, 2009

**Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.**

**Blum K,** Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs WB, Waite RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D, Liu Y, Helman M, Simpatico T.

J Addict Res Ther. 2012 Nov 27;3(5):139.PMID:23926462 [Free PMC Article](#)

# SNAPSHOT REWARD DEFICIENCY SYNDROME

**The D2 dopamine receptor gene as a determinant of reward deficiency syndrome.**

**Blum K**, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE.

J R Soc Med. 1996 Jul;89(7):396-400. Review. PMID: 8774539 [Free PMC Article](#)

**Common Phenotype in Patients with Both Food and Substance Dependence: Case Reports.**

Campbell H, Oscar-Berman M, Giordano J, Beley T, Barh D, Downs B, **Blum K**.

J Genet Syndr Gene Ther. 2013 Feb 6;4(122). pii: 1000122. PMID: 23543232 [Free PMC Article](#)

**Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.**

**Blum K**, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA.

Int J Environ Res Public Health. 2011 Dec;8(12):4425-59. doi: 10.3390/ijerph8124425. Epub 2011 Nov 29. PMID: 22408582 [Free PMC Article](#)

**"Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry.**

**Blum K**, Gardner E, Oscar-Berman M, Gold M.

Curr Pharm Des. 2012;18(1):113-8. PMID: 22236117 [Free PMC Article](#)

**Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery.**

**Blum K**, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold M.

J Genet Syndr Gene Ther. 2011 Dec 23;2012(1). pii: S2-001. PMID: 23483116 [Free PMC Article](#)

**Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.**

Blum K, Gold MS.

Med Hypotheses. 2011 Apr;76(4):576-84. doi: 10.1016/j.mehy.2011.01.005. PMID: 21306831

**Attention-deficit-hyperactivity disorder and reward deficiency syndrome.**

**Blum K**, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M.

Neuropsychiatr Dis Treat. 2008 Oct;4(5):893-918. PMID: 19183781 [Free PMC Article](#)

**Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.**

**Blum K**, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE.

J Psychoactive Drugs. 2000 Nov;32 Suppl:i-iv, 1-112. Review. PMID: 11280926

**Reward deficiency syndrome: genetic aspects of behavioral disorders.**

Comings DE, **Blum K**.

Prog Brain Res. 2000;126:325-41. Review. PMID: 11105655

**Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics.**

**Blum K**, Badgaiyan RD, Gold MS.

Cureus. 2015 Oct 12;7(10):e348. doi: 10.7759/cureus.348. Review. PMID: 26623203 [Free PMC Article](#)

**NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity.**

Schoenthaler SJ, **Blum K**, Braverman ER, Giordano J, Thompson B, Oscar-Berman M, Badgaiyan RD, Madigan MA, Dushaj K, Li M, Demotrovics Z, Waite RL, Gold MS.

J Reward Defic Syndr. 2015;1(1):36-45. PMID: 26052556 [Free PMC Article](#)

## Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

**Blum K**, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M.

Postgrad Med. 2009 Nov;121(6):176-96. doi: 10.3810/pgm.2009.11.2087. Review.PMID: 19940429 [Free PMC Article](#)

## Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction.

**Blum K**, Thanos PK, Oscar-Berman M, Febo M, Baron D, Badgaiyan RD, Gardner E, Demetrovics Z, Fahlke C, Haberstick BC, Dushaj K, Gold MS.

J Reward Defic Syndr. 2015;1(3):95-104. Epub 2015 Oct 23. PMID: 27398406 [Free PMC Article](#)

## Dopamine and glucose, obesity, and reward deficiency syndrome.

**Blum K**, Thanos PK, Gold MS.

Front Psychol. 2014 Sep 17;5:919. doi: 10.3389/fpsyg.2014.00919. eCollection 2014. Review.PMID: 25278909 [Free PMC Article](#)

## The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem.

**Blum K**, Wood RC, Braverman ER, Chen TJ, Sheridan PJ.

Funct Neurol. 1995 Jan-Feb;10(1):37-44. Review. PMID: 7649500

## Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research.

Modestino EJ, **Blum K**, Oscar-Berman M, Gold MS, Duane DD, Sultan SGS, Auerbach SH.

J Reward Defic Syndr. 2015;1(1):6-9. doi: 10.17756/jrds.2015-002. Epub 2015 Feb 6. PMID: 26306327 [Free PMC Article](#)

## Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis.

McLaughlin T, **Blum K**, Oscar-Berman M, Febo M, Demetrovics Z, Agan G, Fratantonio J, Gold MS.

J Reward Defic Syndr. 2015;1(1):24-35. PMID: 26065033 [Free PMC Article](#)

## Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

**Blum K**, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M.

Theor Biol Med Model. 2008 Nov 12;5:24. doi: 10.1186/1742-4682-5-24. Review. PMID: 19014506 [Free PMC Article](#)

## Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission.

**Blum K**, Modestino EJ, Febo M, Steinberg B, McLaughlin T, Fried L, Baron D, Siwicki D, Badgaiyan RD.

J Syst Integr Neurosci. 2017 May;3(3). doi: 10.15761/JSIN.1000163. Epub 2017 May 11. PMID: 28736624 [Free PMC Article](#)

## Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems.

Gold MS, **Blum K**, Febo M, Baron D, Modestino EJ, Elman I, Badgaiyan RD.

Front Biosci (Schol Ed). 2018 Mar 1;10:309-325. PMID: 29293435

## Substance use disorder a bio-directional subset of reward deficiency syndrome.

**Blum K**, Gold M, Demetrovics Z, Archer T, Thanos PK, Baron D, Badgaiyan RD.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1534-1548. PMID: 28410131

## Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome.

Febo M, **Blum K**, Badgaiyan RD, Baron D, Thanos PK, Colon-Perez LM, Demetrovics Z, Gold MS.

Front Biosci (Landmark Ed). 2017 Jan 1;22:669-691. Review. PMID: 27814639

## Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs.

**Blum K**, Simpatico T, Febo M, Rodriguez C, Dushaj K, Li M, Braverman ER, Demetrovics Z, Oscar-Berman M, Badgaiyan RD.

Mol Neurobiol. 2017 Jul;54(5):3753-3758. doi: 10.1007/s12035-016-9934-y. Epub 2016 May 31. PMID: 27246565 [Free PMC Article](#)

## Weight gain is associated with reduced striatal response to palatable food.

Stice E, Yokum S, **Blum K**, Bohon C.

J Neurosci. 2010 Sep 29;30(39):13105-9. doi: 10.1523/JNEUROSCI.2105-10.2010. PMID: 20881128 [Free PMC Article](#)

## **Alcoholism: scientific basis of a neuropsychogenetic disease.**

**Blum K**, Trachtenberg MC.

Int J Addict. 1988 Aug;23(8):781-96. Review. PMID:2906332

## **Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures.**

Modestino EJ, Reinhofer A, **Blum K**, Amenechi C, O'Toole P.

Front Biosci (Landmark Ed). 2018 Mar 1;23:1370-1379.PMID:29293439

## **Altered Dopamine Synaptic Markers in Postmortem Brain of Obese Subjects.**

Wu C, Garamszegi SP, Xie X, Mash DC.

Front Hum Neurosci. 2017 Aug 3;11:386. doi: 10.3389/fnhum.2017.00386. eCollection 2017.PMID:28824395 [Free PMC Article](#)

## **Effects of chronic methamphetamine on psychomotor and cognitive functions and dopamine signaling in the brain.**

Thanos PK, Kim R, Delis F, Rocco MJ, Cho J, Volkow ND.

Behav Brain Res. 2017 Mar 1;320:282-290. doi: 10.1016/j.bbr.2016.12.010. Epub 2016 Dec 16.PMID:27993694

## **Target identification and validation in brain reward dysfunction.**

Alguacil LF1, González-Martín C2.

Drug Discov Today. 2015 Mar;20(3):347-52. doi: 10.1016/j.drudis.2014.10.014

## **Linking online gaming and addictive behavior: converging evidence for a general reward deficiency in frequent online gamers.**

Hahn T, Notebaert KH, Dresler T, Kowarsch L, Reif A, Fallgatter AJ.

Front Behav Neurosci. 2014 Nov 10;8:385. doi: 10.3389/fnbeh.2014.00385. eCollection 2014.PMID:25426039 [Free PMC Article](#)

## **Targeted expression of $\mu$ -opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward.**

Cui Y, Ostlund SB, James AS, Park CS, Ge W, Roberts KW, Mittal N, Murphy NP, Cepeda C, Kieffer BL, Levine MS, Jentsch JD, Walwyn WM, Sun YE, Evans CJ, Maidment NT, Yang XW.

Nat Neurosci. 2014 Feb;17(2):254-61. doi: 10.1038/nn.3622. Epub 2014 Jan 12.PMID: 24413699 [Free PMC Article](#)

## **Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse.**

Rovai L, Maremmani AG, Pacini M, Pani PP, Rugani F, Lamanna F, Schiavi E, Mautone S, Dell'Osso L, Maremmani I.

Riv Psichiatr. 2013 Jan-Feb;48(1):1-9. doi: 10.1708/1228.13610. Review. PMID: 23438696

## **Limbic responses to reward cues correlate with antisocial trait density in heavy drinkers.**

Oberlin BG, Dziedzic M, Bragulat V, Lehigh CA, Talavage T, O'Connor SJ, Kareken DA.

Neuroimage. 2012 Mar;60(1):644-52. doi: 10.1016/j.neuroimage.2011.12.043. Epub 2011 Dec 28.PMID:22227139 [Free PMC Article](#)

## **Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users.**

Nestor L, Hester R, Garavan H.

Neuroimage. 2010 Jan 1;49(1):1133-43. doi: 10.1016/j.neuroimage.2009.07.022. Epub 2009 Jul 23.PMID: 19631753 [Free PMC Article](#)

## **Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients.**

Brandacher G, Winkler C, Aigner F, Schwelberger H, Schroecksadel K, Margreiter R, Fuchs D, Weiss HG.

Obes Surg. 2006 May;16(5):541-8.PMID: 16687019

## **Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome.**

Bowirrat A, Oscar-Berman M.

Am J Med Genet B Neuropsychiatr Genet. 2005 Jan 5;132B(1):29-37. Review.PMID:15457501

## **Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa.**

Linazaro G, van Blercom N, Lasa A.

Neurologia. 2004 Apr;19(3):117-27. Review. Spanish. PMID:15088161

# SNAPSHOT PRECISION ADDICTION MANAGEMENT (PAM)

## **LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.**

**Blum K**, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T.

Adv Ther. 2008 Sep;25(9):894-913. doi: 10.1007/s12325-008-0093-z. PMID: 18781289

## **DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human.**

**Blum K**, Meshkin B, Downs BW.

Med Hypotheses. 2006;66(5):1008-18. Epub 2006 Jan 5. PMID: 16403602

## **Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS).**

**Blum K**, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM.

Med Hypotheses. 2007;68(4):844-52. Epub 2006 Oct 27

## **Addiction Treatment in America: After Money or Aftercare?**

Miller D, Miller M, **Blum K**, Badgaiyan RD, Febo M.

J Reward Defic Syndr. 2015 Oct 21;1(3):87-94. PMID: 26835513

## **Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic.**

**Blum K**, Jacobs W, Modestino EJ, DiNubile N, Baron D, McLaughlin T, Siwicki D, Elman I, Moran M, Braverman ER, Thanos PK, Badgaiyan RD.

SEJ Surg Pain. 2018 Oct 4;1(1):1-11 PMID: 29911684

## **Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)<sup>TM</sup> as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.**

**Blum K**, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold SM.

J Behav Addict. 2014 Sep;3(3):149-56. doi: 10.1556/JBA.3.2014.019. Epub 2014 Aug 26. Review. PMID: 25317338 [Free PMC Article](#)

## **Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?**

**Blum K**, Oscar-Berman M, Blum SH, Madigan MA, Waite RL, McLaughlin T, Barh D.

J Alcohol Drug Depend. 2014 Jul;2(3). pii: 161. Epub 2014 May 29. No abstract available. PMID: 27512720 [Free PMC Article](#)

## **Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis.**

Baron D, **Blum K**, Chen A, Gold M, Badgaiyan RD.

J Am Osteopath Assoc. 2018 Feb 1;118(2):115-118. doi: 10.7556/jaoa.2018.026. PMID: 29379966

## **Physical Exercise Interventions for Drug Addictive Disorders.**

Archer T, Badgaiyan RD, **Blum K**.

J Reward Defic Syndr Addict Sci. 2017;3(1):17-20. Epub 2017 May 29. No abstract available. PMID:29034367 [Free PMC Article](#)

## **Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?**

**Blum K**, Gold M, Clark HW, Dushaj K, Badgaiyan RD.

Subst Use Misuse. 2016 Oct 14;51(12):1674-1679. Epub 2016 Jul 27. PMID: 27462930 [Free PMC Article](#)

## **Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality.**

**Blum K**, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z, Dushaj K, Badgaiyan RD.

Clin Med Rev Case Rep. 2015;2(8). pii: 076. Epub 2015 Dec 17. No abstract available. PMID: 26900600 [Free PMC Article](#)

## The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery.

**Blum K**, Thompson B, Demetrovics Z, Femino J, Giordano J, Oscar-Berman M, Teitelbaum S, Smith DE, Roy AK, Agan G, Fratantonio J, Badgaiyan RD, Gold MS.

J Reward Defic Syndr. 2015;1(1):46-64. PMID: 26306329 [Free PMC Article](#)

## Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward.

**Blum K**, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS.

J Reward Defic Syndr. 2015;1(1):20-23. PMID: 26306328 [Free PMC Article](#)

## A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.

Gold MS, Badgaiyan RD, **Blum K**.

Psychiatr Clin North Am. 2015 Sep;38(3):419-62. doi: 10.1016/j.psc.2015.05.011. Review. PMID: 26300032

## Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?

**Blum K**, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M.

Clin Med Rev Case Rep. 2015;2(1). pii: 018. No abstract available. PMID: 26225358 [Free PMC Article](#)

## A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain.

**Blum K**, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, Li M, Dushaj K, Madigan MA, Hauser M, Simpatico T, Barh D.

J Genet Syndr Gene Ther. 2014 Jan 27;5(1):213. No abstract available. PMID:24883230 [Free PMC Article](#)

## Drug abuse relapse rates linked to level of education: can we repair hypodopaminergic-induced cognitive decline with nutrient therapy?

**Blum K**, Schoenthaler SJ, Oscar-Berman M, Giordano J, Madigan MA, Braverman ER, Han D.

Phys Sportsmed. 2014 May;42(2):130-45. doi: 10.3810/psm.2014.05.2065. PMID: 24875980

## Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

**Blum K**, Oscar-Berman M, Badgaiyan RD, Palomo T, Gold MS.

Med Hypotheses. 2014 May;82(5):606-14. doi: 10.1016/j.mehy.2014.02.019. Epub 2014 Feb 26. PMID: 24636783 [Free PMC Article](#)

## Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™

Downs B, Oscar-Berman M, Waite R, Madigan M, Giordano J, Beley T, Jones S, Simpatico T, Hauser M, Borsten J, Marcelo F, Braverman E, Lohmann R, Dushaj K, Helman M, Barh D, Schoenthaler S, Han D, **Blum K**.

J Genet Syndr Gene Ther. 2013 Jun 3;4(136):14318.PMID:24077767 [Free PMC Article](#)

## Long term Suboxone™ emotional reactivity as measured by automatic detection in speech.

Hill E, Han D, Dumouchel P, Dehak N, Quatieri T, Moehs C, Oscar-Berman M, Giordano J, Simpatico T, Barh D, **Blum K**.

PLoS One. 2013 Jul 9;8(7):e69043. doi: 10.1371/journal.pone.0069043. Print 2013. Erratum in: PLoS One. 2013;8(8):doi/10.1371/annotation/be0b3a26-c1bc-4d92-98c1-c516acc8dcf2. Barh, Debmalaya [added]. PMID:23874860 [Free PMC Article](#)

## Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation.

**Blum K**, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, Barh D.

J Genet Syndr Gene Ther. 2012 May 31;3(3):1000116.PMID:23264885 [Free PMC Article](#)

## The addictive brain: all roads lead to dopamine.

**Blum K**, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D.

J Psychoactive Drugs. 2012 Apr-Jun;44(2):134-43. Review. PMID: 22880541

## Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

**Blum K**, Chen TJ, Bailey J, Bowirrat A, Femino J, Chen AL, Simpatico T, Morse S, Giordano J, Damle U, Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh D, Oscar-Berman M.

Mol Neurobiol. 2011 Dec;44(3):250-68. doi: 10.1007/s12035-011-8206-0. Epub 2011 Sep 24. PMID:2194809 [Free PMC Article](#)

### **Attention-deficit-hyperactivity disorder and reward deficiency syndrome.**

**Blum K**, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M.

Neuropsychiatr Dis Treat. 2008 Oct;4(5):893-918. PMID:19183781 [Free PMC Article](#)

### **Gene \Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome.**

Chen TJ, **Blum K**, Waite RL, Meshkin B, Schoolfield J, Downs BW, Braverman EE, Arcuri V, Varshavskiy M, Blum SH, Mengucci J, Reuben C, Palomo T.

Adv Ther. 2007 Mar-Apr;24(2):402-14. PMID: 17565932

### **A commentary on the pathogenesis and biochemical profile of alcohol-induced depression.**

**Blum K**, Wallace JE, Hall WC.

J Psychoactive Drugs. 1986 Apr-Jun;18(2):161-2. No abstract available. PMID: 3016221

### **A commentary on neurotransmitter restoration as a common mode of treatment for alcohol, Blum, K, cocaine and opiate abuse.**

Integr. Psych. 6:199 204, 1989.

## **SNAPSHOT OF ANIMAL MODELS**

### **Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice.**

Figueiredo A, Hamilton J, Marion M, **Blum K**, Kaczocha M, Haj-Dahmane S, Deutsch D, Thanos PK.

J Reward Defic Syndr Addict Sci. 2017;3(2):21-27. Epub 2017 Oct 31. PMID:29367955 [Free PMC Article](#)

### **Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z.**

Febo M, **Blum K**, Badgaiyan RD, Perez PD, Colon-Perez LM, Thanos PK, Ferris CF, Kulkarni P, Giordano J, Baron D, Gold MS.

PLoS One. 2017 Apr 26;12(4):e0174774. doi: 10.1371/journal.pone.0174774. eCollection 2017. PMID: 28445527 [Free PMC Article](#)

### **Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior.**

Thanos PK, Hamilton J, O'Rourke JR, Napoli A, Febo M, Volkow ND, **Blum K**, Gold M.

Oncotarget. 2016 Apr 12;7(15):19111-23. doi: 10.18632/oncotarget.8088. PMID: 26992232 [Free PMC Article](#)

### **Ethanol ingestive behavior as a function of central neurotransmission.**

**Blum K**, Briggs AH, Trachtenberg MC.

Experientia. 1989 May 15;45(5):444-52. Review. PMID: 2566510

### **Narcotic antagonism of seizures induced by a dopamine-derived tetrahydroisoquinoline alkaloid.**

Experientia. 1988 Sep 15;44(9):751-3. PMID:2843397

### **Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice.**

**Blum K**, Briggs AH, Trachtenberg MC, Delallo L, Wallace JE.

Alcohol. 1987 Nov-Dec;4(6):449-56. PMID: 2829941

### **Regional brain [Met]-enkephalin in alcohol-preferring and non-alcohol-preferring inbred strains of mice.**

**Blum K**, Briggs AH, Wallace JE, Hall CW, Trachtenberg MA.

Experientia. 1987 Apr 15;43(4):408-10. PMID: 3569490

### **Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol.**

Trachtenberg MC, **Blum K**.

Am J Drug Alcohol Abuse. 1987;13(3):365-72. Review. PMID: 2825513

### **Enkephalinase inhibition by thiorphan and subsequent response of ethanol, normorphine and enkephalins on mouse vas deferens.**

**Blum K**, Wallace JE, DeLallo L, Briggs AH.

Funct Neurol. 1986 Apr-Jun;1(2):156-64. PMID: 3301556

### Opioid peptides and alcoholism: genetic deficiency and chemical management.

**Blum K**, Topel H.

Funct Neurol. 1986 Jan-Mar;1(1):71-83. Review. No abstract available. PMID: 2956168

### Methionine enkephalin as a possible neuromodulator of regional cerebral blood flow.

**Blum K**, Gaskill H, DeLallo L, Briggs AH, Hall W.

Experientia. 1985 Jul 15;41(7):932-3. PMID: 4007131

### Evidence for the importance of the "genotype" theory in alcohol seeking behavior: a commentary.

**Blum K**, Wallace JE, Briggs AH, Trachtenberg MC.

Alcohol Drug Res. 1985-1986;6(6):455-61. PMID: 3015159

### Supersensitivity to norepinephrine induced by prenatal exposure to ethanol.

**Blum K**, Dalterio S, Briggs AH, DeLallo LJ, Hall CW.

Eur J Pharmacol. 1984 Nov 13;106(2):415-7. PMID: 6529982

### Ethanol acceptance as a function of genotype amounts of brain [Met]enkephalin.

**Blum K**, Elston SF, DeLallo L, Briggs AH, Wallace JE.

Proc Natl Acad Sci U S A. 1983 Nov;80(21):6510-2. PMID: 6579537 [Free PMC Article](#)

### Clonidine enhancement of ethanol withdrawal in mice.

**Blum K**, Briggs AH, DeLallo L.

Subst Alcohol Actions Misuse. 1983;4(1):59-63. No abstract available. PMID: 6684796

### Alcohol and central nervous system peptides.

**Blum K.**

Subst Alcohol Actions Misuse. 1983;4(2-3):73-87. No abstract available. PMID: 6316574

### Whole brain methionine-enkephalin of ethanol-avoiding and ethanol-preferring c57BL mice.

**Blum K**, Briggs AH, DeLallo L, Elston SF, Ochoa R.

Experientia. 1982 Dec 15;38(12):1469-70. PMID: 6891340

### Reduced leucine-enkephalin--like immunoreactive substance in hamster basal ganglia after long-term ethanol exposure.

**Blum K**, **Briggs AH**, **Elston SF**, **DeLallo L**, **Sheridan PJ**, **Sar M.**

Science. 1982 Jun 25;216(4553):1425-7. PMID: 7089531

### Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains.

Elston SF, **Blum K**, DeLallo L, Briggs AH.

Pharmacol Biochem Behav. 1982 Jan;16(1):13-5. PMID: 7199182

### Opioid responses of isoquinoline alkaloids (TIQs).

**Blum K**, DeLallo L, Briggs AH, Hamilton MG.

Prog Clin Biol Res. 1982;90:387-98. No abstract available. PMID: 7111325

### On the mechanism of methadone-induced alcohol consumption in humans.

**Blum K**, Briggs AH, DeLallo L.

Subst Alcohol Actions Misuse. 1982;3(1-2):1-4. No abstract available. PMID: 6291178

### Holism: a social pharmacological approach to drug-seeking behavior.

**Blum K**, Briggs AH, Cull JG.

J Psychoactive Drugs. 1981 Oct-Dec;13(4):369-71. No abstract available. PMID: 7338745

### Ethanol preference as a function of genotypic levels of whole brain enkephalin in mice.

**Blum K**, Briggs AH, Elston SF, DeLallo L.

Toxicol Eur Res. 1981 Sep;3(5):261-2. No abstract available. PMID: 7340005

### In vivo formation of isoquinoline alkaloids: effect of time and route of administration of ethanol.

Hamilton MG, **Blum K**, Hirst M.

Adv Exp Med Biol. 1980;126:73-86. No abstract available. PMID: 7405709



### **Psychogenetics of drug seeking behavior.**

**Blum K**, Briggs AH, Elston SF, DeLallo L.

Subst Alcohol Actions Misuse. 1980;1(3):255-7. No abstract available. PMID: 7347918

### **Genotype dependent responses to ethanol and normorphine on vas deferens of inbred strains of mice.**

**Blum K**, Briggs AH, DeLallo L, Elston SF.

Subst Alcohol Actions Misuse. 1980;1(5-6):459-65. No abstract available. PMID: 7302794

### **Naloxone antagonizes the action of low ethanol concentrations on mouse vas deferens.**

**Blum K**, Briggs AH, DeLallo L, Elston SF, Hirst M.

Subst Alcohol Actions Misuse. 1980;1(4):327-34. No abstract available. PMID: 7302784

### **Perinatal exposure to delta 9-THC in mice: altered enkephalin and norepinephrine sensitivity in vas deferens.**

Dalterio S, Blum K, DeLallo L, Sweeney C, Briggs A, Bartke A.

Subst Alcohol Actions Misuse. 1980;1(5-6):467-71. No abstract available. PMID:6272434

### **Opiate-like activity of salsolinol on the electrically stimulated guinea pig ileum.**

Hamilton MG, Hirst M, **Blum K**.

Life Sci. 1979 Dec 24;25(26):2205-10. No abstract available. PMID: 542098

### **Alcohol euphoria: possible mediation via endorphinergic mechanisms.**

Verebey K, **Blum K**.

J Psychedelic Drugs. 1979 Oct-Dec;11(4):305-11. No abstract available. PMID: 230360

### **Identification of an isoquinoline alkaloid after chronic exposure to ethanol.**

Hamilton MG, **Blum K**, Hirst M.

Alcohol Clin Exp Res. 1978 Apr;2(2):133-7. PMID: 350076

### **Putative role of isoquinoline alkaloids in alcoholism: a link to opiates.**

**Blum K**, Hamilton MG, Hirst M, Wallace JE.

Alcohol Clin Exp Res. 1978 Apr;2(2):113-20. Review. PMID: 350073

### **Analgesic effects of 3-carboxysalsolinol alone and in combination with morphine.**

Marshall A, Hirst M, **Blum K**.

Experientia. 1977 Jun 15;33(6):754-5. PMID: 891738

### **Isoquinoline alkaloids as possible regulators of alcohol addiction.**

**Blum K**, Hamilton MG, Meyer EK, Hirst M, Marshall A.

Lancet. 1977 Apr 9;1(8015):799-800. No abstract available. PMID: 66592

### **Intensification of amphetamine-induced excitation by methysergide, a serotonergic receptor blocker.**

**Blum K**, Wallace JE, Meyer E, Schwertner HA.

Experientia. 1977 Feb 15;33(2):213-5. PMID: 844561

### **Effects of delta9 tetrahydrocannabinol (delta9-THC) on amphetamine-aggregate toxicity in mice.**

**Blum K**, Briggs AH.

Curr Ther Res Clin Exp. 1977 Feb;21(2):241-4. No abstract available. PMID: 403059

### **Naloxone-induced inhibition of ethanol dependence in mice.**

**Blum K**, Futterman S, Wallace JE, Schwertner HA.

Nature. 1977 Jan 6;265(5589):49-51. No abstract available. PMID: 556802

### **Enhancement of ethanol-induced withdrawal convulsions by blockade of 5-hydroxytryptamine receptors.**

**Blum K**, Wallace JE, Schwertner HA, Eubanks JD.

J Pharm Pharmacol. 1976 Nov;28(11):832-5. PMID: 11292

### **Suppression of ethanol withdrawal by dopamine.**

**Blum K**, Eubanks JD, Wallace JE, Schwertner HA.

Experientia. 1976 Apr 15;32(4):493-5. PMID: 944645

### **Morphine suppression of ethanol withdrawal in mice.**

**Blum K**, Wallace JE, Schwerter HA, Eubanks JD.

Experientia. 1976 Jan 15;32(1):79-82. PMID: 942927

### **Possible role of tetrahydroisoquinoline alkaloids in postalcohol intoxication states.**

**Blum K**, Eubanks JD, Wallace JE, Schwertner H, Morgan WW.

Ann N Y Acad Sci. 1976;273:234-46. No abstract available. PMID: 1072352

### **Morphine withdrawal reactions in male and female mice.**

**Blum K**, Eubanks JD, Wiggins B, Wallace JE.

Am J Drug Alcohol Abuse. 1976;3(2):363-8. PMID: 1036445

### **Enhancement of alcohol withdrawal convulsions in mice by haloperidol.**

**Blum K**, Eubanks JD, Wallace JE, Hamilton H.

Clin Toxicol. 1976;9(3):427-34. PMID: 986285

### **Fetal consequences of chronic methadone administration to pregnant rats: methodological problems.**

McDonald LK, Maddux JF, **Blum K**.

Curr Ther Res Clin Exp. 1975 Mar;17(3):308-17. No abstract available. PMID: 805024

### **Ethanol narcosis in mice: serotonergic involvement.**

**Blum K**, Wallace JE, Calhoun W, Tabor RG, Eubanks JD.

Experientia. 1974 Sep 15;30(9):1053-4. No abstract available. PMID: 4413287

### **Effects of catecholamine synthesis inhibition on ethanol-induced withdrawal symptoms in mice.**

**Blum K**, Wallace JE.

Br J Pharmacol. 1974 May;51(1):109-11. PMID: 4474904 [Free PMC Article](#)

### **Reduction of acute alcoholic intoxication by alpha amino acids: glycine and serine.**

**Blum K**, Wallace JE, Friedman RN.

Life Sci. 1974 Feb 1;14(3):557-65. No abstract available. PMID: 4856787

### **Pineal gland: evidence for an influence on ethanol preference in male Syrian hamsters.**

Reiter RJ, **Blum K**, Wallace JE, Merritt JH.

Comp Biochem Physiol A Comp Physiol. 1974 Jan;47(1):11-6. No abstract available. PMID: 4148997

### **Effect of the pineal gland on alcohol consumption by congenitally blind male rats.**

Reiter RJ, **Blum K**, Wallace JE, Merritt JH.

Q J Stud Alcohol. 1973 Sep;34(3):937-9. No abstract available. PMID: 4742700

### **Soporific action of ethanol in mice: possible role of biogenic amines.**

**Blum K**, Calhoun W, Wallace JE, Merritt JH, Geller I.

Pharmacol Biochem Behav. 1973 May-Jun;1(3):271-6. No abstract available. PMID: 4272868

### **L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice.**

**Blum K**, Calhoun W, Merritt J, Wallace JE.

Nature. 1973 Apr 6;242(5397):407-9. No abstract available. PMID: 4735636

### **A possible relationship between the pineal gland and ethanol preference in the rat.**

**Blum K**, Merritt JH, Reiter RJ, Wallace JE.

Curr Ther Res Clin Exp. 1973 Jan;15(1):25-30. No abstract available. PMID:4631379

### **Diethanolamine: a possible weak agonist-antagonist to ethanol.**

**Blum K**, Wallace JE, Ryback RS, Geller I.

Eur J Pharmacol. 1972 Aug;19(2):218-22. No abstract available. PMID: 5071792

### **Effects of catecholamine synthesis inhibition on ethanol narcosis in mice.**

**Blum K**, Merritt JH, Wallace JE, Owen R, Hahn JW, Geller I.

Curr Ther Res Clin Exp. 1972 Jun;14(6):324-9. No abstract available. PMID: 4625804

### **Synergy of ethanol and putative neurotransmitters: glycine and serine.**

**Blum K**, Wallace JE, Geller I.

Science. 1972 Apr 21;176(4032):292-4. PMID:5019782

### **The effects of low-dose combinations of D-amphetamine and cocaine on experimentally induced conflict in the rat.**

Geller I, Hartmann RJ, **Blum K**.

Curr Ther Res Clin Exp. 1972 Apr;14(4):220-4. No abstract available. PMID: 4623601

### **Interaction effects of ethanol and pyrazole in laboratory rodents.**

**Blum K**, Geller I, Wallace JE.

Br J Pharmacol. 1971 Sep;43(1):67-73. PMID: 5136465 Free PMC Article

### **Effects of nicotine, nicotine monomethiodide, lobeline, chlordiazepoxide, meprobamate and caffeine on a discrimination task in laboratory rats.**

Geller I, Hartmann R, **Blum K**.

Psychopharmacologia. 1971;20(4):355-65. No abstract available. PMID: 5561657

### **Protection against acute alcoholic intoxication with diethanolamine-rutin.**

Geller I, Campbell ND, **Blum K**.

Res Commun Chem Pathol Pharmacol. 1970 May;1(3):383-94. No abstract available. PMID: 5535660

### **Effects of vodka and bourbon on sleeping time in mice.**

**Blum K**, Ryback RS, Geller I.

Q J Stud Alcohol. 1970 May;5:Suppl 5:62-6. No abstract available. PMID:5450665

### **The effects of 5-HTP on para-Chlorophenylalanine (p-CPA) attenuation of "conflict" behavior.**

Geller I, **Blum K**.

Eur J Pharmacol. 1970 Mar;9(3):319-24. No abstract available. PMID: 5440301

### **Effects of chlordiazepoxide and pentobarbital on conflict behavior in rats.**

**Blum K**.

Psychopharmacologia. 1970;17(5):391-8. No abstract available. PMID:5522999

### **The effect of dopamine and other catecholamines on neuromuscular transmission.**

**Blum K**.

Arch Int Pharmacodyn Ther. 1969 Oct;181(2):297-306. No abstract available. PMID: 4326551